RxDoctor Payments DataLook up a doctor →

David Hill, MD

Critical Care Medicine · Waterbury, CTNPI 1033226584

Payments from drug & device makers

$348,977in general payments, 2019–2025

Across 949 payments — averaging $367.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$118K
  • GSK$95K
  • Sanofi$54K
  • Regeneron Healthcare Solutions, Inc.$21K
  • Boehringer Ingelheim$14K
  • Amphastar Pharmaceuticals, Inc.$9K
  • plus $38K from 44 others
$904in research payments, 2019–2025

Across 9 payments — averaging $100.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$904

What the payments were for

  • Consulting fees$18,45010%
  • Speaking & faculty fees$151,68479%
  • Travel & lodging$3,9272%
  • Food & beverage$18,66410%
  • Education$3410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$348,977 in reported general payments places this provider in the 95th percentile of 51 critical care medicine providers in Connecticut.

See all critical care medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$106,005
Medicare patients
308
Services billed
1,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter240$257,922
Breo ElliptaFluticasone/Vilanterol223$141,033
Dupixent PenDupilumab31$129,094
Dupixent SyringeDupilumab22$102,681
Fasenra PenBenralizumab17$96,143
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr96$71,690
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$63,699
SymbicortBudesonide/Formoterol Fumarate61$21,617
Spiriva RespimatTiotropium Bromide28$20,578
XolairOmalizumab12$16,350
Incruse ElliptaUmeclidinium Bromide31$13,784
Advair HfaFluticasone Propion/Salmeterol12$12,850
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate53$12,285
DuleraMometasone/Formoterol17$11,874
Arnuity ElliptaFluticasone Furoate36$11,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$94,796$495,881626 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$118,378$94,698132 claims
Boehringer IngelheimSpiriva Respimat$14,479$20,57828 claims
Genentech, Inc.Xolair$1,408$16,35012 claims
MerckDulera$39$11,87417 claims
Mylan Inc.Wixela Inhub$12$7,28253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 critical care medicine providers in Connecticut.

Other critical care medicine in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →